|
|
|
| Value of Serum 25-(OH)D in Evaluating the Degree of Liver Fibrosis in Patients with Type 2 Diabetes Mellitus Complicated with NAFLD |
| XU Jian-hao, JU Feng |
| Department of Laboratory Medicine, Jianhu County Hospital, Nantong University 224700 |
|
|
|
|
Abstract 【Objective】 To explore the value of serum 25-(OH)D in evaluating the degree of liver fibrosis in patients with type 2 diabetes mellitus complicated with non-alcoholic fatty liver disease (NAFLD). 【Methods】 In this study, 60 patients with type 2 diabetes mellitus complicated with NAFLD were selected as the observation group, and 60 patients with type 2 diabetes mellitus admitted in the same period were selected as the control group. The serum levels of 25-(OH)D, FPG, 2hPG and HbA1c were compared between the two groups. Meanwhile, Spearman correlation coefficient was used to analyze the correlation between 25-(OH)D level and stages of liver fibrosis. 【Results】 There was no significant difference in the levels of FPG, 2hPG and HbA1c between the two groups (P>0.05). The level of 25-(OH)D in the observation group was significantly lower than that that in the control group (P<0.05). Levels of 25-(OH)D in patients of the observation group were significantly different from their stages of liver fibrosis:S1>S2>S3>S4(P<0.05).The correlation analysis showed that the level of 25-(OH)D was negatively correlated with the stages of liver fibrosis (P<0.05). 【Conclusion】 The level of 25-(OH)D in patients with type 2 diabetes complicated with NAFLD is significantly reduced. The level of 25-(OH)D is negatively correlated with the stages of liver fibrosis, which can provide reference to evaluate the stages of liver fibrosis in patients with type 2 diabetes mellitus and NAFLD.
|
|
Received: 20 May 2019
|
|
|
|
|
|
[1] Fox CS, Golden SH, Anderson C, et al. Update on prevention of cardiovascular disease in adults with Type 2 diabetes mellitus in light of recent evidence: a scientific statement from the american heart association and the american diabetes association[J].Diabetes Care,2015, 38(9):1777-1803.
[2] 李斐, 曲震理. 西格列汀联合二甲双胍治疗2型糖尿病伴非酒精性脂肪肝的临床研究[J].中国临床药理学杂志, 2018, 34(5):518-520.
[3] 王思明, 王默, 李红霞, 等. 人血清25-羟基维生素D水平与心血管病危险因素的相关性研究[J].心肺血管病杂志, 2016, 35(9):729-733.
[4] 中华医学会肝脏病学分会脂肪肝和酒精性肝病学组. 非酒精性脂肪性肝病诊断标准(一)[J].新医学, 2005, 7(6):364.
[5] 中华医学会糖尿病学分会. 中国2型糖尿病防治指南(2010年版)[J].中国医学前沿杂志(电子版), 2011, 3(6):54-109.
[6] 刘丽, 张宇. 利拉鲁肽注射液对2型糖尿病合并非酒精性脂肪肝患者肝脏脂肪沉积的影响[J].肝脏, 2018, 23(4):338-340.
[7] 杨丽弘 , 廖鑫 , 张晗 , 等. 2型糖尿病合并非酒精性脂肪肝肝纤维化与血清25-羟维生素D水平的关系研究[J].中国糖尿病杂志, 2018,26(2):117-122.
[8] 王天宝, 嵇兴梅, 都健,等. 健康体检人群血清25-羟基维生素D水平与非酒精性脂肪肝的相关性[J].中华骨质疏松和骨矿盐疾病杂志, 2013, 6(2):121-125.
[9] 蔡雯, 董正惠, 王淑霞, 等. 非酒精性脂肪性肝病患者血清25-羟基维生素D水平与相关因素的临床分析[J].临床肝胆病杂志, 2015,31(7):1059-1062. |
|
|
|
2020, Vol. 37 
